The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mult Scler
Hlavní autoři: Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2017
Témata:
Short Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891690/
https://ncbi.nlm.nih.gov/pubmed/28304217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517695468
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky